Literature DB >> 8607894

Limited heterogeneity of rearranged T cell receptor V alpha and V beta transcripts in synovial fluid T cells in early stages of rheumatoid arthritis.

D C Fischer1, B Opalka, A Hoffmann, W Mayr, H D Haubeck.   

Abstract

OBJECTIVE: The identification of activated T cells in synovial fluid and synovium, and the association of rheumatoid arthritis (RA) with specific HLA-DR restriction elements, strongly suggest that these T cells play a critical role in the etiology and pathogenesis of RA. Analysis of the T cell receptor (TCR) repertoire in the early stages of RA might be an approach to identify those T cells involved in the initiation and/or perpetuation of the disease.
METHODS: TCR V alpha and V beta transcripts of synovial T cells, sampled at the early stages of RA, were amplified by reverse transcriptase-polymerase chain reaction. HLA-DR subtyping was determined by serologic analysis and dot-blot hybridization of polymerase chain reaction amplification products using digoxigenin-labeled, sequence-specific oligonucleotide probes.
RESULTS: Our findings showed a limited heterogeneity of V alpha and V beta TCRs in synovial fluid T cells, and a preferential usage of TCR V alpha 17 in early RA. In contrast, in the later stages of RA, a more polyclonal TCR V alpha and V beta gene usage was observed.
CONCLUSION: Our results support the view that induction of RA is driven by an oligoclonal immune response to an unknown antigen. These findings also suggest a pathogenetic role for V alpha 17 T cells in the early stages of RA.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8607894     DOI: 10.1002/art.1780390313

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  2 in total

Review 1.  T cell receptor usage in autoimmune disease.

Authors:  P Moss; J Bell
Journal:  Springer Semin Immunopathol       Date:  1999

2.  Novel immunosuppressive effect of FK506 by augmentation of T cell apoptosis.

Authors:  Y Hashimoto; N Matsuoka; A Kawakami; M Tsuboi; T Nakashima; K Eguchi; T Tomioka; T Kanematsu
Journal:  Clin Exp Immunol       Date:  2001-07       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.